PR94349

LUXEMBOURG, Feb. 1, 2022 /PRNewswire=KYODO JBN/ --

CordenPharma, a leading, full-service Contract Development & Manufacturing

Organization (CDMO) supplying APIs, Excipients, Drug Products, and associated

Packaging services, announced today the completion of the acquisition of three

manufacturing facilities from Vifor Pharma, to be ultimately renamed Corden

Pharma Fribourg S.A. (including its Ettingen branch) in Switzerland, and Corden

Pharma Lisbon S.A. in Portugal.

Logo - https://mma.prnewswire.com/media/1173757/CordenPharma_Logo.jpg

Dr. Michael Quirmbach, Chief Executive Officer & President of CordenPharma

said, "We welcome the three sites and their employees as new members to the

CordenPharma Group and look forward to working with Vifor in the future to

supply Vifor Pharma's finished drug products, including to their already

existing customers. The acquired pharma sites have a well-trained workforce

with great cultural fit, state-of-the art infrastructure, and a strong

compliance track record. This excellent opportunity aligns well with our

strategy to broaden our CDMO capabilities."

The acquisition of the Vifor Pharma manufacturing sites will expand

CordenPharma's capabilities and capacities in the manufacturing of non-sterile

drug product dosage forms, including but not limited to, Oral Solid Dosage

(OSD) forms such as tablets and capsules. With the addition of these three new

facilities, CordenPharma's global network now consists of twelve locations (11

GMP sites and 1 R&D laboratory), supported by > 2,600 employees generating

expected sales of over 800 Mio € in 2022.

View Press Release on CordenPharma's Website (

https://c212.net/c/link/?t=0&l=en&o=3429409-1&h=571045297&u=https%3A%2F%2Fwww.cordenpharma.com%2Fcordenpharma-completes-acquisition-of-3-facilities-from-vifor-pharma&a=View+Press+Release+on+CordenPharma%27s+Website

)

About CordenPharma

CordenPharma, the global pharmaceutical service & manufacturing platform of

International Chemical Investors Group (ICIG), is a full-service partner in the

Contract Development & Manufacturing (CDMO) of APIs, Excipients, Drug Products,

and associated Packaging Services. Through a growing network of cGMP facilities

across Europe and the US organized under five Technology Platforms -- Peptides,

Lipids & Carbohydrates, Injectables, Highly Potent & Oncology, and Small

Molecules -- CordenPharma experts translate complex processes and projects at

any stage of development into high-value products.

For more information about CordenPharma, contact us (

https://c212.net/c/link/?t=0&l=en&o=3429409-1&h=4116846697&u=https%3A%2F%2Fwww.cordenpharma.com%2Fcontact-us%2F&a=contact+us

) or visit https://cordenpharma.com.

SOURCE: CordenPharma

CONTACT: North America, abby.thompson@cordenpharma.com; Europe & Asia,

eva.schaub@cordenpharma.com